| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Case Report of Severe Type B Lactic Acidosis Following First Dose of Nivolumab in a VHL-Mutated Metastatic Renal Cell Carcinoma
|
Nakajima, Erica
|
|
2017
|
|
1 |
p. 83-88
|
artikel
|
| 2 |
Adjuvant Sunitinib for Renal Cell Carcinoma: Still at the Beginning of the Road
|
Carretero-González, Alberto
|
|
2018
|
|
1 |
p. 1-3
|
artikel
|
| 3 |
Adjuvant Therapy in Renal Cell Cancer
|
Jackson-Spence, Francesca
|
|
|
|
1 |
p. 17-22
|
artikel
|
| 4 |
Adjuvant Therapy in Renal Cell Carcinoma: Are We Ready for Prime Time?
|
Wang, Luke L.
|
|
|
|
1 |
p. 1-11
|
artikel
|
| 5 |
Adjuvant Therapy in Renal Cell Carcinoma: Current Status and Future Directions
|
Kazarian, Austin G.
|
|
|
|
1 |
p. 9-20
|
artikel
|
| 6 |
Antigenic targets in clear cell renal cell carcinoma
|
Schindler, Nicholas R.
|
|
|
|
1 |
p. 81-91
|
artikel
|
| 7 |
Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden
|
Maia, Manuel Caitano
|
|
2017
|
|
1 |
p. 65-70
|
artikel
|
| 8 |
A Systematic Review of Systemic Treatment Options for Advanced Non-Clear Cell Renal Cell Carcinoma
|
Osterman, Chelsea K.
|
|
|
|
1 |
p. 15-27
|
artikel
|
| 9 |
Axitinib beyond first-line therapy of Metastatic Renal Cell Carcinoma: Real World Data from the STAR-TOR registry
|
Uhlig, Annemarie
|
|
|
|
1 |
p. 37-48
|
artikel
|
| 10 |
Belzutifan versus Everolimus in Advanced Kidney Cancer: A Commentary on LITESPARK-005 Trial from ESMO 2023
|
Gulati, Shuchi
|
|
|
|
1 |
p. 23-24
|
artikel
|
| 11 |
BRCA1-Associated Protein 1 (BAP-1) as a Prognostic and Predictive Biomarker in Clear Cell Renal Cell Carcinoma: A Systematic Review
|
Gulati, Shuchi
|
|
|
|
1 |
p. 23-35
|
artikel
|
| 12 |
Cell-free Circulating Tumor DNA (ctDNA) in Metastatic Renal Cell Carcinoma (mRCC): Current Knowledge and Potential Uses
|
Hahn, Andrew W.
|
|
2019
|
|
1 |
p. 7-13
|
artikel
|
| 13 |
Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma
|
Tannir, Nizar M.
|
|
|
|
1 |
p. 29-39
|
artikel
|
| 14 |
Clinical Trials Corner
|
Parikh, Mamta
|
|
2019
|
|
1 |
p. 79-80
|
artikel
|
| 15 |
Clinical Trials Corner
|
Powles, Thomas
|
|
2017
|
|
1 |
p. 89-91
|
artikel
|
| 16 |
Clinical Trials Corner
|
Powles, Thomas
|
|
2018
|
|
1 |
p. 69-71
|
artikel
|
| 17 |
Clinical Trials Corner: A Promising New Drug Class in Treating Metastatic Renal Cell Carcinoma
|
Parikh, Mamta
|
|
|
|
1 |
p. 59-60
|
artikel
|
| 18 |
Clinical Trials Corner: Is the Era of Theranostics Imminent?
|
Parikh, Mamta
|
|
|
|
1 |
p. 25-26
|
artikel
|
| 19 |
Clinical Trials Corner: Nephrectomy in the New Year
|
Parikh, Mamta
|
|
|
|
1 |
p. 81-82
|
artikel
|
| 20 |
Clinical Trials Corner: Raising the SABR to Renal Cell Carcinoma
|
Parikh, Mamta
|
|
|
|
1 |
p. 17-18
|
artikel
|
| 21 |
Clinical Trials Corner: The Challenge to Establish Optimal Treatment After Progression on Checkpoint Inhibitors
|
Parikh, Mamta
|
|
|
|
1 |
p. 93-94
|
artikel
|
| 22 |
Clinical Trials Corner: The dreaded IVC thrombus - optimizing management
|
Parikh, Mamta
|
|
|
|
1 |
p. 27-29
|
artikel
|
| 23 |
Comparative Evaluation of Safety and Efficacy of Alternate Schedule (AS) of Sunitinib in Asian and Non-Asian Patient Population for the Treatment of Metastatic Renal Cell Cancer (mRCC): A Meta-Analysis
|
Joshi, Amit
|
|
|
|
1 |
p. 37-51
|
artikel
|
| 24 |
Comparison of Oncological and Functional Outcomes of Radical Versus Partial Nephrectomy for cT1b Renal Cell Carcinoma: A Two-Centre, Matched Analysis
|
van den Brink, Luna
|
|
|
|
1 |
p. 51-59
|
artikel
|
| 25 |
Cost-Effectiveness of Immunotherapy Treatments for Renal Cell Carcinoma: A Systematic Review
|
Philip, Errol J.
|
|
|
|
1 |
p. 47-62
|
artikel
|
| 26 |
Cystic Renal Lesions: A Systematic Review of Diagnosis and Treatment
|
Ibañez Vázquez, Laura
|
|
|
|
1 |
p. 95-114
|
artikel
|
| 27 |
Efficacy, Effectiveness, and Safety of Interventions for Von Hippel-Lindau Associated Renal Cell Carcinoma: A Systematic Literature Review
|
Jonasch, Eric
|
|
|
|
1 |
p. 1-15
|
artikel
|
| 28 |
Efficacy of Therapy vs Surveillance in Patients with Resected Early-Stage Intermediate to High-Risk Renal Cell Carcinoma
|
Major, C. Kendall
|
|
|
|
1 |
p. 19-35
|
artikel
|
| 29 |
Emerging Antibody-Drug Conjugate Therapies and Targets for Metastatic Renal Cell Carcinoma
|
Gottlich, Harrison C.
|
|
|
|
1 |
p. 161-172
|
artikel
|
| 30 |
Erratum to: Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma
|
Sharma, Akanksha
|
|
|
|
1 |
p. 15
|
artikel
|
| 31 |
Erratum to: SETD2 Regulates the Methylation of Translation Elongation Factor eEF1A1 in Clear Cell Renal Cell Carcinoma
|
Hapke, Robert
|
|
|
|
1 |
p. 13-14
|
artikel
|
| 32 |
Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma1
|
Sharma, Akanksha
|
|
|
|
1 |
p. 69-79
|
artikel
|
| 33 |
Fibrinogen Levels in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab: Results of a Multicenter Prospective Trial
|
Tsimafeyeu, Ilya
|
|
|
|
1 |
p. 115-121
|
artikel
|
| 34 |
Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)
|
Stukalin, Igor
|
|
2018
|
|
1 |
p. 31-36
|
artikel
|
| 35 |
Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma
|
Carlo, M.I.
|
|
2017
|
|
1 |
p. 49-56
|
artikel
|
| 36 |
Genomic and Transcriptomic Characteristics of Tumors of Patients with Metastatic Clear Cell Renal Cell Carcinoma Clinically Benefiting from First-Line Treatment with Ipilimumab Plus Nivolumab
|
Tripathi, Nishita
|
|
|
|
1 |
p. 137-145
|
artikel
|
| 37 |
Impact of Aspirin and Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs on Outcomes in Patients with Metastatic Renal Cell Carcinoma
|
Hamieh, Lana
|
|
2018
|
|
1 |
p. 37-46
|
artikel
|
| 38 |
Influences of Age and Comorbidities on Indication for Partial Nephrectomy: A Systematic Review
|
Cignoli, Daniele
|
|
|
|
1 |
p. 49-65
|
artikel
|
| 39 |
In Memoriam: Chris Wood
|
Lara Jr, Primo N.
|
|
|
|
1 |
p. 1
|
artikel
|
| 40 |
Kidney Cancer: A New Forum for Impactful Scientific Interactions
|
Lara Jr., Primo N.
|
|
2017
|
|
1 |
p. 1
|
artikel
|
| 41 |
Kidney Cancer Incidence in California: End of the Trend?
|
Morris, Cyllene R.
|
|
2017
|
|
1 |
p. 71-81
|
artikel
|
| 42 |
Landmark Trials in Renal Cancer
|
Vaishampayan, Ulka
|
|
2018
|
|
1 |
p. 11-21
|
artikel
|
| 43 |
Metastasectomy in Advanced Renal Cell Carcinoma: A Systematic Review
|
Achkar, Tala
|
|
2019
|
|
1 |
p. 31-40
|
artikel
|
| 44 |
MET Inhibitors for Papillary Renal Cell Carcinoma
|
Brundage, James Nicholas
|
|
|
|
1 |
p. 67-80
|
artikel
|
| 45 |
Molecular Classification of Renal Cell Carcinoma and Its Implication in Future Clinical Practice
|
Casuscelli, Jozefina
|
|
2017
|
|
1 |
p. 3-13
|
artikel
|
| 46 |
Molecularly Defined Renal Carcinomas
|
Amann-Arévalo, Marta
|
|
|
|
1 |
p. 31-44
|
artikel
|
| 47 |
Nephrectomy Status in the Context of Cabozantinib Treatment
|
Esteghamat, Naseem
|
|
|
|
1 |
p. 1-2
|
artikel
|
| 48 |
Nephrotoxicity Associated with Contemporary Renal Cell Carcinoma Regimens: A Systematic Review and Meta-Analysis
|
Dukkipati, Akasha
|
|
|
|
1 |
p. 147-159
|
artikel
|
| 49 |
Non-Surgical Ablative Treatment of Distant Extracranial Metastases for Renal Cell Carcinoma: A Systematic Review
|
Verbiest, Annelies
|
|
2018
|
|
1 |
p. 57-67
|
artikel
|
| 50 |
Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC)
|
Yip, Steven M.
|
|
2017
|
|
1 |
p. 41-47
|
artikel
|
| 51 |
Patient-Derived Renal Cell Carcinoma Xenografts Capture Tumor Genetic Profiles and Aggressive Behaviors
|
Beserra, Adriano O.
|
|
|
|
1 |
p. 11-22
|
artikel
|
| 52 |
PD-L1 Expression and Treatment Implications in Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review
|
Jang, Albert
|
|
|
|
1 |
p. 31-46
|
artikel
|
| 53 |
Perioperative Statin Use and Acute Kidney Injury in Patients Undergoing Partial Nephrectomy
|
Joshi, Shreyas S.
|
|
2018
|
|
1 |
p. 47-55
|
artikel
|
| 54 |
“PROBE”ing the Role of Cytoreductive Nephrectomy in Advanced Renal Cancer
|
Bell, Hannah
|
|
|
|
1 |
p. 3-9
|
artikel
|
| 55 |
Prognostic Value of Histologic Subtype and Treatment Modality for T1a Kidney Cancers1
|
Siev, Michael
|
|
|
|
1 |
p. 49-58
|
artikel
|
| 56 |
Radiation Therapy for Renal Cell Carcinoma
|
Choi, Rachel
|
|
2019
|
|
1 |
p. 1-6
|
artikel
|
| 57 |
Radical Nephrectomy is the Treatment of Choice for Complex, Localized Renal Tumors
|
Meissner, Matthew A.
|
|
2018
|
|
1 |
p. 5-9
|
artikel
|
| 58 |
Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib – Results of NCI/CTEP Protocol 9048
|
Semrad, Thomas J
|
|
2019
|
|
1 |
p. 51-61
|
artikel
|
| 59 |
Real-Word Experience of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis)
|
Zhang, Hanbo
|
|
|
|
1 |
p. 21-29
|
artikel
|
| 60 |
Real-World Outcome of 173 Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC) Cases: The Experience of the Center Group for Genitourinary Tumors
|
Martín, Almudena
|
|
2019
|
|
1 |
p. 41-50
|
artikel
|
| 61 |
Renal Function: Implications on the Surgical Treatment of RCC
|
Janetschek, Günter
|
|
|
|
1 |
p. 1-8
|
artikel
|
| 62 |
Stereotactic Body Radiation Therapy for Renal Cell Carcinoma with Inferior Vena Cava Thrombus – Initial Experience Report and Literature Review
|
Freifeld, Yuval
|
|
2019
|
|
1 |
p. 71-77
|
artikel
|
| 63 |
Systematic Review: ClearCode 34 – A Validated Prognostic Signature in Clear Cell Renal Cell Carcinoma (ccRCC)
|
Ghatalia, Pooja
|
|
2018
|
|
1 |
p. 23-29
|
artikel
|
| 64 |
Systematic Review of Treatment of Metastatic Non-Clear Cell Renal Cell Carcinoma
|
Brown, Jason R.
|
|
|
|
1 |
p. 53-68
|
artikel
|
| 65 |
Systematic Review: Perioperative Systemic Therapy for Metastatic Renal Cell Carcinoma
|
Pilié, Patrick G.
|
|
2017
|
|
1 |
p. 57-64
|
artikel
|
| 66 |
Targeted Literature Review of Outcomes to Initial Systemic Therapy for Advanced/Metastatic Non-Clear Cell Renal Cell Carcinoma in Observational Studies
|
Calhoun, Shawna R.
|
|
|
|
1 |
p. 123-136
|
artikel
|
| 67 |
Targeted Therapy and Immunotherapy: Effect of Body Mass Index on Clinical Outcomes in Patients Diagnosed with Metastatic Renal Cell Carcinoma
|
Bergerot, Paulo Gustavo
|
|
2019
|
|
1 |
p. 63-70
|
artikel
|
| 68 |
The ‘Achilles Heel’ of Metabolism in Renal Cell Carcinoma: Glutaminase Inhibition as a Rational Treatment Strategy
|
Hoerner, Christian R.
|
|
2019
|
|
1 |
p. 15-29
|
artikel
|
| 69 |
The Prognostic Value of DNA Methylation Markers in Renal Cell Cancer: A Systematic Review
|
Peters, Inga
|
|
|
|
1 |
p. 3-13
|
artikel
|
| 70 |
Therapeutic Sequencing in Metastatic Renal Cell Carcinoma
|
Maia, Manuel Caitano
|
|
2017
|
|
1 |
p. 15-29
|
artikel
|
| 71 |
The Role of Targeted Radiation Therapy in the Treatment of Renal Cell Carcinoma
|
Lee, Albert
|
|
|
|
1 |
p. 45-50
|
artikel
|
| 72 |
Thickness of Perirenal Fat Predicts the Growth Pattern of Renal Cell Carcinoma
|
Kashiwagi, Eiji
|
|
|
|
1 |
p. 41-48
|
artikel
|
| 73 |
Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC—A Possible Path Forward
|
Harshman, L.C.
|
|
2017
|
|
1 |
p. 31-40
|
artikel
|
Tijdschrift beschrijving